Literature DB >> 1831668

Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG.

L Frölich1, J Kornhuber, R Ihl, J Fritze, K Maurer, P Riederer.   

Abstract

Serum and cerebrospinal fluid (CSF) from 25 patients with dementia of Alzheimer type (DAT) and 25 controls were assayed for concentrations of albumin and IgG. The severity of dementia was rated with the Mini Mental State Examination. The CSF/serum ratio for albumin and IgG as well as the IgG index were used to evaluate blood-CSF barrier function in the respective groups. The control group was matched for age, sex and the indirect alcohol parameters, mean corpuscular volume and gamma-glutamyltranspeptidase. There were no signs of dysfunction of the blood-CSF barrier for proteins or signs of local synthesis of IgG in the central nervous system (CNS) of the demented patients. The permeability of the blood-CSF barrier appeared to be unrelated to dementia severity. The data do not support the hypothesis that a pathological leakage through the blood-CSF barrier facilitates the entry of extraneuronal proteins to the CNS, which might contribute to the pathophysiological process in DAT.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831668     DOI: 10.1007/bf02279767

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  36 in total

1.  The clinical diagnosis of Alzheimer's disease.

Authors:  J P Wade; T R Mirsen; V C Hachinski; M Fisman; C Lau; H Merskey
Journal:  Arch Neurol       Date:  1987-01

2.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

3.  Observations on the brains of demented old people.

Authors:  B E Tomlinson; G Blessed; M Roth
Journal:  J Neurol Sci       Date:  1970-09       Impact factor: 3.181

4.  CSF and serum concentrations of albumin and IgG in Alzheimer's disease.

Authors:  A D Kay; C May; N M Papadopoulos; R Costello; J R Atack; J S Luxenberg; N R Cutler; S I Rapoport
Journal:  Neurobiol Aging       Date:  1987 Jan-Feb       Impact factor: 4.673

5.  Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia.

Authors:  I Alafuzoff; R Adolfsson; G Bucht; B Winblad
Journal:  J Neurol Sci       Date:  1983 Aug-Sep       Impact factor: 3.181

6.  Serum immunoglobulins and cognitive status in the elderly: i. A population study.

Authors:  D Cohen; C Eisdorfer
Journal:  Br J Psychiatry       Date:  1980-01       Impact factor: 9.319

7.  Pathological verification of ischemic score in differentiation of dementias.

Authors:  W G Rosen; R D Terry; P A Fuld; R Katzman; A Peck
Journal:  Ann Neurol       Date:  1980-05       Impact factor: 10.422

8.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Validity of clinical diagnosis in dementia: a prospective clinicopathological study.

Authors:  P K Mölsä; L Paljärvi; J O Rinne; U K Rinne; E Säkö
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

10.  Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.

Authors:  R E Tanzi; J F Gusella; P C Watkins; G A Bruns; P St George-Hyslop; M L Van Keuren; D Patterson; S Pagan; D M Kurnit; R L Neve
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

View more
  18 in total

1.  Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases.

Authors:  Sarah Jesse; Johannes Brettschneider; Sigurd D Süssmuth; Bernhard G Landwehrmeyer; Christine A F von Arnim; Albert C Ludolph; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2010-12-25       Impact factor: 4.849

2.  Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future.

Authors:  Gene L Bowman; Joseph F Quinn
Journal:  Aging health       Date:  2008-02-01

Review 3.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

Review 4.  Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.

Authors:  William A Banks
Journal:  Adv Drug Deliv Rev       Date:  2011-12-17       Impact factor: 15.470

5.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

6.  Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Dharmini C Mehta; Jennifer L Short; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2013-06-22       Impact factor: 4.200

7.  Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models.

Authors:  Sarah Logan; Thiago Arzua; Scott G Canfield; Emily R Seminary; Samantha L Sison; Allison D Ebert; Xiaowen Bai
Journal:  Compr Physiol       Date:  2019-03-14       Impact factor: 9.090

Review 8.  Can infections cause Alzheimer's disease?

Authors:  Francis Mawanda; Robert Wallace
Journal:  Epidemiol Rev       Date:  2013-01-24       Impact factor: 6.222

Review 9.  Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Authors:  Michelle A Erickson; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-07       Impact factor: 6.200

Review 10.  MRI measurements of Blood-Brain Barrier function in dementia: A review of recent studies.

Authors:  Rajikha Raja; Gary A Rosenberg; Arvind Caprihan
Journal:  Neuropharmacology       Date:  2017-10-28       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.